WEST Search History

Hide Items | Restore | Clear | Cancel

updated search 8/9/05

DATE: Tuesday, August 09, 2005

Hide?	Set Name	Query	Hit Count
		DB=USPT; PLUR=YES; OP=OR	
☐	L1	sugan.asn. or sugen.asn.	145
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR	
☐	L2	sugan.asn. or sugen.asn.	497
☐	L3	L2 and (method or process).clm.	187
☐	L4	(identif$ or measur$ or detect$ or determin$ or modulat$ or testing$ or screen$ or (high near through$)).clm.	1251469
☐	L5	L4 and l3	117
☐	L6	diagnos$.clm.	31907
☐	L7	L6 and l3	14
☐	L8	L7 or l5	117
☐	L9	L8 and (indolinones or $linones).clm.	40
☐	L10	l2 and (identif$ or screen$ or test$).clm.	40
☐	L11	L10 and (normal$ or control).clm.	11
☐	L12	L11 and (indolinones or indolinone or $linones).clm.	0
☐	L13	L10 and (normal$ or control).clm.	11
☐	L14	L11 and (indolinones or indolinone or $linones)	7
☐	L15	l14 and l11	7
☐	L16	l2 and measur$.clm. and compar$.clm. and detect$.clm.	5
☐	L17	l2 and (src or frk or btk or csk or abl or zap70 or zap-70 or fes or fps or fak or jak or ack or yes or fyn or lyn or lck or blk or hck or fgr or yrk or ras or raf).clm.	32

END OF SEARCH HISTORY

Dev Growth Differ. 2005 May;47(4):233-42. Related Articles, Links

Full text
biosilweb.synergy.com

Postnatal changes in the expression of p60c-Src in mouse testes.

Gye MC, Choi JK, Ahn HS, Kim YS.

Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 133-791, Korea. mcgye@hanyang.ac.kr

Src-family non-receptor tyrosine kinases are involved in signaling pathways which mediate cell growth, differentiation, transformation and tissue remodeling in various organs. In an effort to elucidate functional involvement of p60c-Src (c-Src) in spermatogenesis, the postnatal changes in c-src mRNA and c-Src protein together with kinase activity and subcellular localization were examined in mouse testes. c-src mRNA levels in testes increased during the first 2 weeks of postnatal development (PND). Following a decrease at puberty (PND 28), the c-src mRNA levels re-increased at adulthood (PND 50). Src kinase activity of testes was low at PND 7 but sharply increased prepubertally (PND 15) and highest at adulthood. Upon Western blotting, the level of c-Src protein was the highest in prepubertal testes but rather decreased in adult testes at PND 50. In adult testes, ubiquitination of c-Src proteins was apparent compared with immature one at PND 7, suggesting active turnover of c-Src by ubiquitination. In immature testes, c-Src immunoreactivity was largely found in the cytoplasm of the Sertoli cells. By contrast, in pubertal and adult testes intense immunoreactivity was localized at the adluminal and basal cytoplasm of Sertoli cells bearing elongated spermatids and early germ cells, respectively. The immunoreactivity of c-Src in the Leydig cells was increased during pubertal development, suggesting the functional involvement of c-Src in differentiated adult Leydig cells. Throughout postnatal development, some spermatogonia and spermatocytes showed intensive c-Src immunoreactivity compared with other germ cells, suggesting a possible role of c-Src in germ cell death. Taken together, it is suggested that c-Src may participate in the remodeling of the seminiferous epithelia and functional differentiation of Leydig cells during the postnatal development of mouse testes.

PMID: 15921498 [PubMed - in process]

Generate Collection | Print

Search Results - Record(s) 1 through 32 of 32 returned.

1. 20040266855. 13 Jul 04. 30 Dec 04. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors. Liang, Congxin, et al. 514/414; 548/455 A61K031/404 C07D43/02.

2. 20040185547. 26 Jan 04. 23 Sep 04. Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases. Mohammadi, Moosa, et al. 435/194; 702/19 G06F019/00 G01N033/48 G01N033/50 C12N009/12.

3. 20040157909. 16 Dec 03. 12 Aug 04. 4-Aryl substituted indolinones. Cui, Jingrong, et al. 514/414; 548/465 A61K031/404 C07D43/02.

4. 20040138255. 14 Jul 03. 15 Jul 04. Phosphate mimics and methods of treatment using phosphatease inhibitors. Huang, Ping, et al. 514/311; 514/381 514/415 514/485 514/520 514/562 514/602 546/176 548/252 548/503 558/412 560/12 564/86 A61K031/47 A61K031/41 A61K031/405 A61K031/325 A61K031/277 A61K031/18 A61K031/195.

5. 20040106630. 02 Dec 03. 03 Jun 04. Bicyclic protein kinase inhibitors. Tang, Peng Cho, et al. 514/265.1; 514/248 514/249 514/300 514/418 544/236 544/280 544/350 546/113 548/484 C07D471/02 C07D487/02 A61K031/519.

6. 20040106618. 02 Dec 03. 03 Jun 04. Bicyclic protein kinase inhibitors. Tang, Peng Cho, et al. 514/248; 514/249 514/265.1 544/236 544/281 544/350 A61K031/519 A61K031/503 A61K031/498 C07D487/02.

7. 20040097497. 27 Aug 03. 20 May 04. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors. Tang, Peng Cho, et al. 514/228.2; 514/232.2 514/252.06 514/254.09 514/255.05 514/256 514/397 514/406 544/144 544/238 544/333 544/373 544/405 544/60 548/312.1 548/364.7 548/465 A61K031/541 A61K031/5377 A61K031/506 A61K031/497 A61K031/496 A61K031/4178 A61K031/416 C07D43/14.

8. 20040092546. 12 Aug 03. 13 May 04. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors. Wei, Chung Chen, et al. 514/303; 514/406 546/119 548/361.1 C07D471/02 C07D43/04 A61K031/4745 A61K031/416.

9. 20040053924. 21 Jul 03. 18 Mar 04. 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Liang, Congxin, et al. 514/234.5; 514/252.16 514/253.04 514/265.1 514/300 544/117 544/127 544/281 544/362 546/113 A61K031/5377 A61K031/519 A61K031/496 A61K031/4745 C07D471/02.

10. 20030191128. 25 Feb 03. 09 Oct 03. 2-indolinone derivatives as modulators of protein kinase activity. Tang, Peng Cho, et al. 514/243; 514/265.1 514/300 514/383 514/397 514/414 544/184 544/280 546/113 548/266.4 548/312.1 548/465 C07D471/02 C07D487/02 C07D43/02 A61K031/53 A61K031/519 A61K031/4196 A61K031/4178 A61K031/405.

11. 20030119819. 10 Sep 02. 26 Jun 03. 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors. Liang, Congxin, et al. 514/217.08; 514/323 514/414 514/80 540/602 546/201 548/414 548/455 A61K031/675 A61K031/55 A61K031/404 A61K031/454

C07D43/14 C07D43/02.

☐ 12. 20030119067. 13 Nov 02. 26 Jun 03. PYK2 related products and methods. Lev, Sima, et al. 435/7.1; 435/194 435/320.1 435/325 435/69.1 514/249 514/266.1 514/311 514/376 G01N033/53 C12N009/12 C12P021/02 C12N005/06 A61K031/498 A61K031/517 A61K031/421 A61K031/47.

☐ 13. 20030069421. 24 Jul 02. 10 Apr 03. 3-(Piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors. Tang, Peng Cho, et al. 544/182; 544/236 544/280 544/295 544/350 544/360 544/362 544/373 C07D487/02 C07D43/14 C07D43/02.

☐ 14. 20030069297. 20 Dec 01. 10 Apr 03. 4-aryl substituted indolinones. Cui, Jingrong Jean, et al. 514/414; 548/465 A61K031/404 C07D43/02 C07D43/14.

☐ 15. 6911446. 26 Jan 01; 28 Jun 05. Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds. Tang; Peng C., et al. 514/252.17; 514/266.2 514/266.21 514/266.23 514/266.24 544/283 544/284 544/291 544/292 544/293. A61K031495 A61K03150 A61K03152 A61P03500 C07D23972.

☐ 16. 6861418. 16 Dec 03; 01 Mar 05. 4-aryl substituted indolinones. Cui; Jingrong, et al. 514/183; 514/319 514/322 514/327 514/408 514/415 514/456 546/199 546/201 548/452 548/465 548/469 548/486 549/396. A61K03133 A61K0314738 C07D20904 C07D20934 C07D31194.

☐ 17. 6683082. 29 Mar 01; 27 Jan 04. Bicyclic protein kinase inhibitors. Tang; Peng Cho, et al. 514/249; 514/264.1 514/265.1 514/80 544/238 544/280 544/350. A61K031/495 A61P035/00 C07D409/00 C07D487/00 C07D471/00.

☐ 18. 6677368. 20 Dec 01; 13 Jan 04. 4-aryl substituted indolinones. Cui; Jingrong, et al. 514/427; 514/183 514/254.09 514/408 514/415 514/418 514/422 514/423 548/452 548/459 548/489 548/560 548/564. A61K031/40 A61K031/33 C07D209/04 C07D207/30.

☐ 19. 6610688. 21 Dec 00; 26 Aug 03. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Liang; Congxin, et al. 514/234.2; 514/234.5 514/252.16 514/265.1 544/117 544/280. C07D487/04 A61K031/519.

☐ 20. 6506763. 30 Jul 01; 14 Jan 03. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity. Tang; Peng Cho, et al. 514/274; 514/314 514/339 514/411 514/418 514/455 544/315 546/152 546/277.7 548/440 548/455 548/486. A61K031/505 A61K031/47 A61K031/35 C07D401/00 C07D209/82.

☐ 21. 6486185. 12 Nov 98; 26 Nov 02. 3-heteroarylidene-2-indolinone protein kinase inhibitors. McMahon; Gerald, et al. 514/359; 514/361 514/397 548/125 548/143 548/202 548/250. C07D403/14 C07D403/06 A61K031/41 A61K031/415.

☐ 22. 6469032. 22 Jan 01; 22 Oct 02. 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease. Tang; Peng Cho, et al. 514/339; 514/359 514/361 514/362 514/363 514/364 514/365 514/372 514/374 514/378 514/380 514/383 514/397 514/406 514/414 514/416. A61K031/401.

☐ 23. 6316635. 15 Apr 99; 13 Nov 01. 2-indolinone derivatives as modulators of protein kinase activity. Tang; Peng Cho, et al. 548/312.1;. C07D403/02 A61K031/417 A61N019/02 A61N031/00 A61N035/00.

☐ 24. 6204267. 01 May 98; 20 Mar 01. Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds. Tang; Peng C., et al. 514/252.17; 514/266.2 514/266.21 514/266.4 544/284 544/285 544/286 544/287 544/288 544/289 544/291 544/292 544/293. A61K031/495 A61K031/505 C07D239/72.

☐ 25. 6133305. 25 Sep 98; 17 Oct 00. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity. Tang; Peng Cho, et al. 514/418; 514/235.2 514/254.09 514/422 514/444 514/445 514/469 514/688 514/764 544/144 544/373 548/485 548/486 548/503 548/509 548/511 548/512 548/518 549/469 549/50 549/58 549/59 562/493 585/25. A61K031/40 C07D209/12 C07D209/34.

☐ 26. 6114371. 12 Nov 98; 05 Sep 00. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors. Tang; Peng Cho, et al. 514/414; 514/235.2 514/323 544/143 544/144 546/201 548/454. A01N043/38 A61K031/535 C07D413/04 C07D401/04 C07D405/04.

☐ 27. 6090838. 04 Jun 98; 18 Jul 00. Methods and compositions for inhibition of adaptor protein/tyrosine kinase interactions. Tang; Peng Cho, et al. 514/414; 548/455. C07D209/04 A61K031/40.

☐ 28. 6066463. 20 May 94; 23 May 00. Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders. Schlessinger; Joseph, et al. 435/7.23; 435/7.1 435/7.2 435/7.24 436/63 436/64. G01N033/574 G01N033/53 G01N033/48.

☐ 29. 5886020. 05 Jun 96; 23 Mar 99. 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease. Tang; Peng Cho, et al. 514/418; 548/486. A61K031/40 C07D209/34.

☐ 30. 5780496. 05 Jun 96; 14 Jul 98. Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions. Tang; Peng Cho, et al. 514/414; 548/455. A61K031/40 C07D209/04.

☐ 31. 5773459. 07 Jun 95; 30 Jun 98. Urea- and thiourea-type compounds. Tang; Peng Cho, et al. 514/445; 514/326 514/327 514/347 514/371 514/426 514/585 514/596 514/597 546/208 546/212 546/216 546/23 546/306 548/196 548/557 548/559 549/63. A61K031/38 C07D333/10.

☐ 32. 5650415. 07 Jun 95; 22 Jul 97. Quinoline compounds. Tang; Peng Cho, et al. 514/312; 514/313 546/153 546/159. C07D213/80 A61K031/44.

Generate Collection | Print

Term	Documents
SRC	12413
SRCS	123
FRK	392
FRKS	7
BTK	712
BTKS	2

CSK	1101
CSKS	17
ABL	4794
ABLS	15
ZAP70	484
(L2 AND (SRC OR FRK OR BTK OR CSK OR ABL OR ZAP70 OR ZAP-70 OR FES OR FPS OR FAK OR JAK OR ACK OR YES OR FYN OR LYN OR LCK OR BLK OR HCK OR FGR OR YRK OR RAS OR RAF).CLM.).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	32

There are more results than shown above. Click here to view the entire set.

Prev Page Next Page Go to Doc#

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, August 09, 2005

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR	
☐	L1	schlessinger.in. or okigaki.in. or gishizky.in.	173
☐	L2	L1 and (pky2 or pyk2 oe pky-2 or pyk-2 or kinase or raf or ras or indolinone or inflammation or inflammatory or connective or crohn or colitis or tissue)	141
☐	L3	l2 and indolinone$.clm.	2
☐	L4	l2 and indolinone$.clm.	2
☐	L5	L1 and (pky2 or pyk2 oe pky-2 or pyk-2 or kinase or raf or ras or connective or crohn or colitis or tissue).clm.	25
☐	L6	l1 and (method or process).clm.	43
☐	L7	l6 and indolin$	2
☐	L8	l6 and indolinon$	2
☐	L9	l6 and indolinone$	2
☐	L10	L6 and (pky2 or pyk2 oe pky-2 or pyk-2 or kinase or raf or ras or connective or crohn or colitis or tissue).clm.	16
☐	L11	(6689806 or 6680335 or 6514981).pn.	6
☐	L12	sugan.asn. or sugen.asn.	497
☐	L13	L12 and (indolinone$.clm. or colitis.clm. or crohn.clm. or connective.clm. or ulcerative.clm. or disease.clm.)	114
☐	L14	L12 and (indolinone$.clm. or colitis.clm. or crohn$.clm. or connective.clm. or ulcerative.clm. or disease.clm.)	114
☐	L15	L12 and ((indolinone$.clm. or colitis.clm. or crohn$.clm. or connective.clm. or ulcerative.clm. or disease.clm.) same (method or process).clm.)	103

END OF SEARCH HISTORY

Generate Collection | Print

Search Results - Record(s) 1 through 50 of 103 returned.

1. 20050125852. 07 May 04. 09 Jun 05. Novel kinases. Caenepeel, Sean, et al. 800/18; 435/194 435/320.1 435/325 435/6 435/69.1 536/23.2 C12Q001/68 A01K067/027 C07H021/04 C12N009/12.

2. 20050107340. 10 Feb 04. 19 May 05. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives. Moon, Malcolm Wilson, et al. 514/80; 514/414 548/410 548/465 A61K031/675 C07D043/02 A61K031/405.

3. 20050084877. 04 May 04. 21 Apr 05. Mammalian protein phosphatases. Plowman, Gregory D., et al. 435/6; 435/196 435/320.1 435/325 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N009/16.

4. 20050054017. 20 Nov 03. 10 Mar 05. Phosphospecific PAK antibodies and diagnostic kits. Smeal, Tod R., et al. 435/7.23; G01N033/574.

5. 20050038066. 05 Aug 04. 17 Feb 05. Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors. Zhang, Fang-Jie, et al. 514/300; 514/414 546/113 548/455 C07D471/02 C07D043/02 A61K031/4745 A61K031/404.

6. 20050032871. 03 Sep 03. 10 Feb 05. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors. Tang, Peng Cho, et al. 514/414; 548/465 A61K031/404 C07D043/02.

7. 20050026184. 20 May 04. 03 Feb 05. Diagnosis and treatment of alk-7 related disorders. Plowman, Gregory D., et al. 435/6; 435/194 435/320.1 435/325 435/69.1 435/7.23 536/23.2 C12Q001/68 G01N033/574 C07H021/04 C12N009/12.

8. 20050009840. 26 Feb 04. 13 Jan 05. Aminoheteroaryl compounds as protein kinase inhibitors. Cui, Jingrong Jean, et al. 514/255.05; 514/255.06 514/340 514/345 544/405 544/406 546/268.1 546/297 A61K031/497 A61K031/4965 C07D43/02.

9. 20050009832. 14 May 04. 13 Jan 05. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors. Sun, Connie Li, et al. 514/249; 544/350 A61K031/498 C07D487/04.

10. 20040266843. 08 Mar 04. 30 Dec 04. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK). Howlett, Anthony R., et al. 514/365; 514/414 A61K031/427 A61K031/404.

11. 20040259158. 27 Feb 04. 23 Dec 04. PYK2 and inflammation. Schlessinger, Joseph, et al. 435/7.1; 514/266.1 514/312 514/418 G01N033/53 A61K031/517 A61K031/47.

12. 20040220189. 20 Feb 04. 04 Nov 04. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors. Sun, Connie Li, et al. 514/249; 544/350 A61K031/498 C07D487/04.

13. 20040204407. 08 Mar 04. 14 Oct 04. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors. Tang, Peng Cho, et al. 514/227.5; 514/235.2 514/254.09 514/323 514/414 544/143 544/373 544/60 546/201 548/465 A61K031/541 A61K031/5377 A61K031/496 A61K031/454 A61K031/404 C07D43/14 C07D413/14 C07D417/14.

14. 20040197792. 15 Jul 03. 07 Oct 04. Novel Kinases. Whyte, David, et al. 435/6; 435/194 435/320.1 435/325 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N009/12.

15. 20040186161. 05 Apr 04. 23 Sep 04. Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives. Sun, Connie Li, et al. 514/414; 548/465 C07D43/02 A61K031/405.

16. 20040157909. 16 Dec 03. 12 Aug 04. 4-Aryl substituted indolinones. Cui, Jingrong, et al. 514/414; 548/465 A61K031/404 C07D43/02.

17. 20040157852. 17 Nov 03. 12 Aug 04. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors. Tang, Peng Cho, et al. 514/250; 544/345 A61K031/498 C07D487/02.

18. 20040157306. 20 Nov 03. 12 Aug 04. Mammalian protein phosphatases. Plowman, Gregory D., et al. 435/196; 435/320.1 435/325 435/69.1 536/23.2 C12P021/06 C07H021/04 C12N009/16.

19. 20040147586. 02 Dec 03. 29 Jul 04. Indolinone derivatives as protein kinase/phosphatase inhibitors. Tang, Peng Cho, et al. 514/414; 548/455 A61K031/404 C07D43/02.

20. 20040138269. 07 Oct 03. 15 Jul 04. Substituted pyrroles as kinase inhibitors. Sun, Connie Li, et al. 514/343; 514/422 514/423 546/276.4 548/517 548/518 548/530 A61K031/4439 A61K031/4025 A61K031/401 C07D43/02.

21. 20040138255. 14 Jul 03. 15 Jul 04. Phosphate mimics and methods of treatment using phosphatease inhibitors. Huang, Ping, et al. 514/311; 514/381 514/415 514/485 514/520 514/562 514/602 546/176 548/252 548/503 558/412 560/12 564/86 A61K031/47 A61K031/41 A61K031/405 A61K031/325 A61K031/277 A61K031/18 A61K031/195.

22. 20040132155. 20 Nov 03. 08 Jul 04. Mammalian protein phosphatases. Plowman, Gregory D., et al. 435/196; 435/320.1 435/325 435/6 435/69.1 536/23.2 C12N009/16 C12Q001/68 C07H021/04.

23. 20040127544. 24 Dec 03. 01 Jul 04. Mannich base prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-indolinone derivatives. Moon, Malcolm Wilson, et al. 514/414; 548/465 A61K031/404 C07D43/14.

24. 20040102510. 08 Sep 03. 27 May 04. 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors. Guan, Huiping, et al. 514/414; 548/465 A61K031/405 C07D43/14.

25. 20040097497. 27 Aug 03. 20 May 04. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors. Tang, Peng Cho, et al. 514/228.2; 514/232.2 514/252.06 514/254.09 514/255.05 514/256 514/397 514/406 544/144 544/238 544/333 544/373 544/405 544/60 548/312.1 548/364.7 548/465 A61K031/541 A61K031/5377 A61K031/506 A61K031/497 A61K031/496 A61K031/4178 A61K031/416 C07D43/14.

26. 20040067531. 11 Jun 03. 08 Apr 04. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds. Tang, Peng Cho, et al. 435/7.1; 514/291 514/411 546/81 548/427 548/429 G01N033/53 C07D471/02 A61K031/4745 A61K031/407 A61K031/403.

27. 20040063773. 14 Apr 03. 01 Apr 04. Pyrrole substituted 2-indolinone protein kinase inhibitors. Tang, Peng Cho, et al. 514/414; 548/465 A61K031/404 C07D43/02.

☐ 28. 20040053924. 21 Jul 03. 18 Mar 04. 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Liang, Congxin, et al. 514/234.5; 514/252.16 514/253.04 514/265.1 514/300 544/117 544/127 544/281 544/362 546/113 A61K031/5377 A61K031/519 A61K031/496 A61K031/4745 C07D471/02.

☐ 29. 20040039196. 13 Jun 03. 26 Feb 04. (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors. Wei, Chung Chen, et al. 540/602; 546/113 546/277.7 548/465 548/484 C07D471/02 C07D43/02.

☐ 30. 20040024010. 10 Mar 03. 05 Feb 04. 3-methylidenyl-2-indolinone modulators of protein kinase. Tang, Pen Cho, et al. 514/300; 514/414 514/418 546/113 548/457 548/465 548/484 C07D471/02 C07D43/04 A61K031/4745 A61K031/404.

☐ 31. 20040018528. 19 May 03. 29 Jan 04. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals. Morimoto, Alyssa, et al. 435/6; 435/7.1 C12Q001/68 G01N033/53.

☐ 32. 20040009549. 31 Dec 02. 15 Jan 04. Method for detecting remote homologues and novel kinases identified with the method. Grigoriev, Igor Vyacheslavovich, et al. 435/69.1; 435/194 435/320.1 435/325 536/23.2 C12P021/02 C12N005/06 C07H021/04 C12N009/12.

☐ 33. 20040005648. 19 Jun 03. 08 Jan 04. PYK2 related products and methods. Lev, Sima, et al. 435/7.23; 435/194 435/320.1 435/338 435/69.1 530/388.26 536/23.2 G01N033/574 C07H021/04 C12N009/12 C12P021/02 C12N005/06.

☐ 34. 20040002534. 23 Jun 03. 01 Jan 04. Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds. Lipson, Ken, et al. 514/414; 514/418 A61K031/404.

☐ 35. 20030216462. 24 Feb 03. 20 Nov 03. (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors. Wei, Chung Chen, et al. 514/414; 548/465 A61K031/405 C07D43/02.

☐ 36. 20030203901. 25 Nov 02. 30 Oct 03. Methods of modulating tyrosine protein kinase function with indolinone compounds. Tang, Peng Cho, et al. 514/228.2; 514/234.5 514/243 514/248 514/250 514/267 514/291 544/184 544/234 544/251 544/345 544/60 546/82 A61K031/541 A61K031/5377 A61K031/519 A61K031/53 A61K031/498 A61K031/502 A61K031/4745 C07D487/02.

☐ 37. 20030199510. 15 Jan 03. 23 Oct 03. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity. Tang, Peng Cho, et al. 514/243; 514/258.1 514/265.1 514/266.2 514/300 514/414 544/184 544/236 544/253 544/280 544/284 544/350 544/405 546/113 C07D487/02 C07D471/02 A61K031/53 A61K031/519 A61K031/517.

☐ 38. 20030191162. 02 Dec 02. 09 Oct 03. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy. Langecker, Peter J., et al. 514/363; 514/364 514/365 514/372 514/378 514/383 514/397 514/406 514/414 A61K031/429 A61K031/427 A61K031/422 A61K031/4245 A61K031/4196 A61K031/4178 A61K031/404 A61K031/416.

☐ 39. 20030191128. 25 Feb 03. 09 Oct 03. 2-indolinone derivatives as modulators of protein kinase activity. Tang, Peng Cho, et al. 514/243; 514/265.1 514/300 514/383 514/397 514/414 544/184 544/280 546/113 548/266.4 548/312.1 548/465 C07D471/02 C07D487/02 C07D43/02 A61K031/53 A61K031/519 A61K031/4196 A61K031/4178 A61K031/405.

☐ 40. 20030176487. 26 Aug 02. 18 Sep 03. 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease. Tang, Peng Cho, et al. 514/418; 548/484 A61K031/404 C07D209/36.

☐ 41. 20030125370. 30 May 02. 03 Jul 03. 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS. Cui, Jingrong, et al. 514/414; 548/465 A61K031/405 C07D43/14 C07D43/02.

☐ 42. 20030119067. 13 Nov 02. 26 Jun 03. PYK2 related products and methods. Lev, Sima, et al. 435/7.1; 435/194 435/320.1 435/325 435/69.1 514/249 514/266.1 514/311 514/376 G01N033/53 C12N009/12 C12P021/02 C12N005/06 A61K031/498 A61K031/517 A61K031/421 A61K031/47.

☐ 43. 20030108946. 19 Feb 02. 12 Jun 03. Indolinone combinatorial libraries and related products and methods for the treatment of disease. Tang, Peng Cho, et al. 435/7.1; 436/518 544/280 548/454 548/484 G01N033/53 C07D487/02 C07D43/02 C07D209/36.

☐ 44. 20030100555. 09 Apr 02. 29 May 03. Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives. Sun, Connie Li, et al. 514/232.8; 514/254.09 514/323 514/414 544/144 544/373 546/209 548/465 A61K031/5377 A61K031/496 A61K031/454 A61K031/404 C07D413/14 C07D43/14.

☐ 45. 20030092917. 15 Feb 02. 15 May 03. 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors. Guan, Huiping, et al. 548/468; C07D43/02 C07D43/14.

☐ 46. 20030083363. 16 Sep 02. 01 May 03. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives. Moon, Malcolm Wilson, et al. 514/414; 514/80 548/414 548/465 A61K031/675 C07F009/547 C07D43/02 A61K031/404.

☐ 47. 20030069297. 20 Dec 01. 10 Apr 03. 4-aryl substituted indolinones. Cui, Jingrong Jean, et al. 514/414; 548/465 A61K031/404 C07D43/02 C07D43/14.

☐ 48. 20030027308. 13 Nov 01. 06 Feb 03. Novel human protein phosphatases identified from genomic sequencing. Plowman, Gregory D., et al. 435/196; 435/320.1 435/325 435/69.1 536/23.2 C12N009/16 C07H021/04 C12P021/02 C12N005/06.

☐ 49. 20020183370. 31 Dec 01. 05 Dec 02. 3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors. Tang, Peng Cho, et al. 514/373; 514/379 514/403 514/414 548/207 548/241 548/360.1 548/454 C07D417/02 C07D413/02 C07D43/02 A61K031/415 A61K031/42.

☐ 50. 20020183364. 13 Dec 01. 05 Dec 02. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds. Tang, Peng Cho. 514/339; 514/414 546/277.4 548/455 A61K031/4439 A61K031/404 C07D43/14 C07D43/02.

Generate Collection | Print

Term	Documents
COLITIS	14680
COLITI	0
CONNECTIVE	34033

CONNECTIVES	252
ULCERATIVE	13064
ULCERATIVES	39
DISEASE	217158
DISEASES	168705
METHOD	2713340
METHODS	1592607
PROCESS	2303332
(L12 AND ((INDOLINONE$.CLM. OR COLITIS.CLM. OR CROHN$.CLM. OR CONNECTIVE.CLM. OR ULCERATIVE.CLM. OR DISEASE.CLM.) SAME (METHOD OR PROCESS).CLM.)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	103

There are more results than shown above. Click here to view the entire set.

Prev Page Next Page Go to Doc#

#14	Search **non-receptor protein tyrosine kinases decrease**	14:45:17
#8	Search **non-receptor protein tyrosine kinases disease**	14:39:07
#7	Search **proline-rich tyrosine kinase 2 (**	14:35:37
#5	Search **pky2**	14:35:16
#4	Search **pky2 abnormal levels**	14:35:07
#3	**Related Articles** for **PubMed** (Select **1533716**)	08:25:43
#1	Search **postgraduate medicine 1992 millikan**	08:23:21

Curr Pharm Des. 2004;10(15):1739-44. Related Articles, Links

The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy.

Navara CS.

Dept. of Obstetrics, Gynecology and Reprod. Sci. and Pittsburgh Development Center University of Pittsburgh 204 Craft Avenue Pittsburgh, PA 15213, USA. cnavara@pdc.magee.edu

The spleen tyrosine kinase Syk is an enigmatic protein tyrosine kinase functional in a number of diverse cellular processes. It is best known as a non-receptor protein tyrosine kinase involved in signal transduction in cells of hematopoietic origin and plays a crucial role in signaling in most of these cells. It is involved in B and T-cell function, platelet aggregation, mast cell signaling, neutrophils and macrophages. Recently it has been found in tissues outside of the hematopoietic lineage. Perhaps the most interesting non-traditional role of Syk is that of a potential tumor suppressor in breast cancer. Absence of Syk protein in primary breast tumors is correlated with poor outcomes. Syk deficient cells have increased motility which is restored to normalcy by replacement with wild-type Syk. Syk also associates with the actin and tubulin cytoskeleton and is an alpha-tubulin kinase. The central role that Syk has in a number of cellular processes makes it an ideal starting point for broad therapeutic targeting.

Publication Types:
- Review
- Review, Tutorial